Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Phase 4

Conditions: Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Prednisolone
Drug: Dexamethasone
Drug: L-Asparaginase
Drug: Vincristine
Drug: Methotrexate
Drug: Doxorubicin
Drug: Daunorubicin
Drug: Cyclophosphamide
Drug: 6-Mercaptopurine
Drug: Cytarabine
Drug: Thioguanine
Drug: Fludarabine
Drug: Imatinib

First Posted Date: 2016-09-09

Last Posted Date: 2016-09-30

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 500

Registration Number: NCT02894645

Locations: 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬
National University Hospital, Singapore, Singapore

and more 1 locations

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Phase 1

Active, not recruiting

Conditions: Lymphoma
DLBCL
Follicular Lymphoma

Interventions: Drug: Tazemetostat
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisolone

First Posted Date: 2016-09-05

Last Posted Date: 2024-10-09

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 214

Registration Number: NCT02889523

Locations: 🇫🇷
APHP - Hôpital Saint Louis, Paris Cedex 10, France
🇫🇷
Centre Henri Becquerel, Rouen, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 28 locations

Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

First Posted Date: 2016-08-26

Last Posted Date: 2024-10-10

Lead Sponsor: Goethe University

Target Recruit Count: 1000

Registration Number: NCT02881086

Locations: 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany

Corticosteroid Reduction in COPD

Phase 4

Completed

Conditions: Lung Diseases, Obstructive
Blood Eosinophil Count
COPD
Glucocorticoids
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Prednisolone

First Posted Date: 2016-08-05

Last Posted Date: 2019-02-08

Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Target Recruit Count: 318

Registration Number: NCT02857842

Locations: 🇩🇰
Bispebjerg University Hospital, Copenhagen, Denmark
🇩🇰
North Zealand Hospital, Copenhagen, Denmark
🇩🇰
Gentofte University Hospital, Hellerup, Denmark

and more 1 locations

Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients

Phase 4

Completed

Conditions: Tracheal Stenosis

Interventions: Drug: Placebo
Drug: Prednisolone

First Posted Date: 2016-08-04

Last Posted Date: 2017-04-04

Lead Sponsor: National Research Institute of Tuberculosis and Lung Disease, Iran

Target Recruit Count: 100

Registration Number: NCT02855502

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

Phase 2

Completed

Conditions: Alcoholic Hepatitis (AH)

Interventions: Drug: Selonsertib
Drug: Prednisolone
Drug: Placebo

First Posted Date: 2016-08-03

Last Posted Date: 2019-02-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 104

Registration Number: NCT02854631

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 41 locations

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

First Posted Date: 2016-07-11

Last Posted Date: 2024-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT02828358

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States

and more 170 locations